Clinical trial · Observational
Long Term Metformin in Women With Polycystic Ovary Syndrome
Effects of Long Term Treatment With Metformin on Clinical, Metabolic and Endocrine Parameters in Women With Polycystic Ovary Syndrome And Increased Metabolic Risk
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators analyzed collection data of 10 years for the efficacy of metformin on body mass, menstrual frequencies, metabolic and hormonal outcomes in women with polycystic ovary syndrome (PCOS) and BMI ≥ 25kg/m2. Each patient's age and height were recorded at baseline. In addition each patient weight, waist circumference, menstrual regularity, fasting glucose, glucose after 120 minute oral glucose tolerance test, luteinizing hormone, follicle stimulating hormone , free and direct testosterone, androstenedione, sex hormone binding globulin, dehydroepiandrosterone sulfate were identified at baseline and at the every follow up visit where available.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- body weight
- timeFrame
- The measurement is assessed in kilograms at the beginning and after every year of taking metformin for 10 years.
- description
- Primary outcome was change in body weight.
- measure
- menstrual frequency
- timeFrame
- The measurement is assessed in number of bleeds per year at the beginning and after every year of taking metformin for 10 years.
- description
- Primary outcome was change in menstrual frequency.
- measure
- free testosterone
- timeFrame
- The measurement is assessed in nmol/L at the beginning and after every year of taking metformin for 10 years.
- description
- Primary outcome was change in levels of free testosterone.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 55 Years
Show eligibility criteria text
Inclusion Criteria: * PCOS phenotype A * BMI≥ 25kg/m2 * metformin 1000mg twice a day for at least one year Exclusion Criteria: * PCOS phenotype B, C, D * BMI \<25kg/m2 * had been treated with spironolactone or oral contraceptives alone or in combination with metformin * had history of bariatric surgery * became pregnant during the observation period * had inability to tolerate metformin, leading to the cessation of drug therapy within first follow up year
References
Publications (0)
Data not yet available